

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in Atlanta, GA

Debiopharm announces the poster presentations of preclinical data for Debio 0123 and clinical data for Debio 1143 and Debio 1347

Lausanne, Switzerland – April 1, 2019 – Debiopharm, (www.debiopharm.com/debiopharm-international/) a global biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including pre-clinical results of Debio 0123 (Selective WEE1 inhibitor), diagnostic molecular screening for Debio 1347 (FGFR inhibitor) and clinical exploratory results for Debio 1143 (IAP¹ inhibitor) at the 2019 Annual AACR meeting in Atlanta, Georgia. These abstract presentations are part of Debiopharm's ongoing oncology programs to investigate the anti-tumor activity and toxicity profile of innovative compounds aimed at treating a broad variety of cancer types.

“These results from our multiple ongoing oncology programs are giving us more insight into the potential of integrating specialized, targeted compounds into current therapeutic strategies.”

- Gregoire Vuagniaux, Director of Translational Pharmacology, Debiopharm International SA

AACR 2019 Abstract Presentations

Compound	Title	Date and Time	N°
Debio 0123	Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123	Tue, April 2nd, 1:00-5:00pm	#4423
Debio 1143	Open-label, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the SMAC mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck	Wed, April 3rd, 8:00-12:00pm	#5001
Debio 1347	Molecular screening of patients with FGFR alterations for a phase 1 (ph1) study with the selective FGFR inhibitor (FGFRi) DEBIO 1347	Wed, April 3rd, 8:00-12:00pm Section 19	#4881

Debiopharm International's commitment to cancer patients

Debiopharm International SA aims to develop innovative therapies that target high unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing and clinical development and then select large pharmaceutical commercialization partners to maximize patient access across the globe.

Find out about our currently clinical trials at patients.debiopharm.com

Visit us www.debiopharm.com/debiopharm-international/

Follow us @DebiopharmNews at twitter.com/DebiopharmNews

Debiopharm International SA Contact

Dawn Haughton

Communication Manager

dawn.haughton@debiopharm.com

Tel: +41 (0)21 321 01 11

¹ IAP= Inhibitor of Apoptosis Proteins